Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Atossa Therapeutics, Inc.

Market Cap 21.18M 18.3M 16.86M 15.78M 29.58M 2.01B 30.03M 199M 77.62M 980M 79.5M 77.81M 3.39B P/E Ratio 2026 *
-0.56x
P/E Ratio 2027 * -0.9x
Enterprise Value 21.18M 18.3M 16.86M 15.78M 29.58M 2.01B 30.03M 199M 77.62M 980M 79.5M 77.81M 3.39B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.87%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day-2.64%
1 week-47.03%
Current month-53.92%
1 month-50.31%
3 months-51.51%
6 months-77.52%
Current year-72.77%
1 week 2.35
Extreme 2.35
4.59
1 month 2.35
Extreme 2.35
5.3
Current year 2.35
Extreme 2.35
10.95
1 year 2.35
Extreme 2.35
19.35
3 years 2.35
Extreme 2.35
34.65
5 years 2.35
Extreme 2.35
147
10 years 2.35
Extreme 2.35
959.85
Manager TitleAgeSince
Chief Executive Officer 75 31/03/2009
Director of Finance/CFO 50 13/10/2025
Chief Tech/Sci/R&D Officer - 30/09/2025
Director TitleAgeSince
Chairman 75 31/03/2009
Director/Board Member 68 02/03/2014
Director/Board Member 74 31/01/2012
Date Insider Type Main position Quantity % Market Cap.
05-11
Ensisheim Partners LLC
OtherCompany 0 0%
05-11Free

Director

10,000 0.1161%
05-11Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
-2.64%-47.03%-81.12%-82.12% 21.18M
+0.74%+0.76%-13.05%-12.68% 43.03B
+2.47%+6.30%+296.89%+527.86% 32.71B
-1.67%-2.97%+11.92%-17.78% 30.29B
+0.56%-1.64%+0.73%+32.49% 29.4B
+1.16%+2.10%+14.27%+22.05% 25.08B
+2.67%+8.70% - - 13.54B
+0.37%+1.86%+54.96%+111.41% 13.35B
-1.25%-2.47%+3.33%+4.84% 12.97B
+0.33%+0.22%+109.14%+76.78% 12.11B
Average +0.28%-3.75%+44.12%+73.65% 21.25B
Weighted average by Cap. +0.66%+0.82%+60.25%+101.38%

Financials

2026 *2027 *
Net sales - -
Net income -38.34M -33.12M -30.52M -28.57M -53.54M -3.64B -54.37M -360M -140M -1.77B -144M -141M -6.14B -44.21M -38.18M -35.19M -32.94M -61.72M -4.2B -62.68M -415M -162M -2.05B -166M -162M -7.08B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
15/06/26 2.395 $ -2.64% 151,266
12/06/26 2.460 $ -4.84% 644,745
11/06/26 2.585 $ -41.25% 1,419,877
10/06/26 4.400 $ -0.23% 29,976
09/06/26 4.410 $ -3.08% 53,900
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.460USD
Average target price
22.75USD
Spread / Average Target
+824.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!